The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...

With a potential buyer not working out, Idorsia has adjusted an existing partnership and restructured bonds to raise cash.

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed ...

Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial ...

US GAAP loss for global business of around CHF 155 million. André C. Muller, Chief Executive Officer of Idorsia, commented: “We were not able to close the envisaged out-licensing agreement for ...

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...